{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:58:53Z","timestamp":1785473933352,"version":"3.56.0"},"reference-count":47,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/13696998.2022.2074193","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T09:21:40Z","timestamp":1651742500000},"page":"640-649","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9681-3388","authenticated-orcid":false,"given":"Jos\u00e9 Ram\u00f3n","family":"Gonz\u00e1lez-Juanatey","sequence":"first","affiliation":[{"name":"Servicio Cardiolog\u00eda, Hospital Cl\u00ednico Universitario de Santiago de Compostela, Santiago De Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1220-6199","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Gonz\u00e1lez-Franco","sequence":"additional","affiliation":[{"name":"Servicio Medicina Interna, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-9228","authenticated-orcid":false,"given":"Patricia","family":"de Sequera","sequence":"additional","affiliation":[{"name":"Servicio Nefrolog\u00eda, Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Valls","sequence":"additional","affiliation":[{"name":"Market Access, Vifor Pharma Group., Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ramirez de Arellano","sequence":"additional","affiliation":[{"name":"Global HEOR, Vifor Pharma Group, Glattbrugg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisenda","family":"Pomares","sequence":"additional","affiliation":[{"name":"Market Access, PharmaLex, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Nieves","sequence":"additional","affiliation":[{"name":"Market Access, PharmaLex, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"issue":"10053","key":"e_1_3_3_2_1","first-page":"640","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the global burden of disease study 2015","volume":"388","author":"Wang H","year":"2016","unstructured":"Wang H, Naghavi M, Allen C, et\u00a0al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the global burden of disease study 2015. The Lancet. 2016;388(10053):640\u20131544.","journal-title":"The Lancet"},{"key":"e_1_3_3_3_1","doi-asserted-by":"crossref","unstructured":"Ballar\u00edn J Garc\u00eda F Ibeas J et\u00a0al. Gu\u00eda de Pr\u00e1ctica Cl\u00ednica sobre la Detecci\u00f3n y el Manejo de la Enfermedad Renal Cr\u00f3nica del Servicio Nacional de Salud [Clinical practice guideline on detection and management of the chronic kidney disease. Ministerio de Sanidad Servicios Sociales e Igualdad. Instituto Aragon\u00e9s de Ciencias de la Salud [Internet]. 2016 [cited 2021 August 17]. Available from: https:\/\/portal.guiasalud.es\/wp-content\/uploads\/2018\/12\/GPC_559_ERC_IACS_compl.pdf.","DOI":"10.46995\/gpc_559"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1228-y"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2018.11.011"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010010079"},{"key":"e_1_3_3_7_1","unstructured":"AEMPS (Spanish Agency for Medicines and Medical Devices). AEMPS online medicinal product information centre (CIMA). AEMPS [Internet]. 2021 [cited 2021 November 18]. Available from: https:\/\/cima.aemps.es\/cima\/publico\/home.html."},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab076"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410853"},{"key":"e_1_3_3_10_1","unstructured":"National Institute for Health and Care Excellence. Patiromer for treating hyperkalaemia: guidance (TA623). National Institute for Health and Care Excellence [Internet]. 2020 [cited 2020 December 9]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta623"},{"key":"e_1_3_3_11_1","unstructured":"VIFOR PHARMA. OPAL-HK CSR. Data on file. 2014."},{"key":"e_1_3_3_12_1","unstructured":"Ortega A Mar\u00edn R Fraga MD. Gu\u00eda de evaluaci\u00f3n econ\u00f3mica e impacto presupuestario en los informes de evaluaci\u00f3n de medicamentos. Gu\u00eda pr\u00e1ctica asociada al programa MADRE v 4.0. [Guideline for economic evaluation and budget impact in drug evaluation reports. Practice guideline associated with the MADRE v 4.0. program]. Sociedad Espa\u00f1ola de Farmacia Hospitalaria. 2021 [cited 2021 July 1]. Available from: https:\/\/gruposdetrabajo.sefh.es\/genesis\/genesis\/Documents\/GUIA_EE_IP_GENESIS-SEFH_19_01_2017.pdf."},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1250-0"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012655"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02212-1"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000552"},{"key":"e_1_3_3_17_1","unstructured":"Robb M Hendry R. Annual report on kidney transplantation. NHS Blood and Transplant [Internet]. 2020 [cited 2021 December 9]. Available from: https:\/\/nhsbtdbe.blob.core.windows.net\/umbraco-assets-corp\/20032\/kidney-annual-report-2019-20-final.pdf."},{"key":"e_1_3_3_18_1","unstructured":"UK Renal Association. UK Renal Registry 22nd Annual Report. UK Renal Association [Internet]. 2018 [cited 2021 December 9]. Available from: https:\/\/ukkidney.org\/about-us\/who-we-are\/uk-renal-registry."},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl382"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001094"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.10.011"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.584102"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/11536310-000000000-00000"},{"key":"e_1_3_3_25_1","unstructured":"Gisbert R Brosa M. Base de Datos de Costes Sanitarios y Ratios Coste-Efectividad Espa\u00f1oles: eSalud [Database of Spanish health costs and cost-effectiveness ratios]. Oblikue Consulting S.L. [Internet]. 2021 [cited 2021 June 2]. Available from: http:\/\/esalud.oblikue.com."},{"key":"e_1_3_3_26_1","first-page":"458","article-title":"An\u00e1lisis de costes y perfil sociocultural del enfermo renal. Impacto de la modalidad de tratamiento [cost analysis and sociocultural profile of kidney patients. Impact of the treatment method]","volume":"34","author":"Lorenzo-Sellares V","year":"2014","unstructured":"Lorenzo-Sellares V, Pedrosa MI, Santana-Exp\u00f3sito B, et\u00a0al. An\u00e1lisis de costes y perfil sociocultural del enfermo renal. Impacto de la modalidad de tratamiento [cost analysis and sociocultural profile of kidney patients. Impact of the treatment method]. Nefrolog\u00eda. 2014;34:458\u2013468. Spanish.","journal-title":"Nefrolog\u00eda"},{"key":"e_1_3_3_27_1","volume-title":"Libro blanco de la poliquistosis renal autosomica dominante (PQRAD) en Espa\u00f1a. Alianza frente a la PQRAD","author":"Caballero Alcalde C","year":"2016","unstructured":"Caballero Alcalde C, Calleja Hern\u00e1ndez MA, Escoda Ruiz L, et\u00a0al. Libro blanco de la poliquistosis renal autosomica dominante (PQRAD) en Espa\u00f1a. Alianza frente a la PQRAD. 2nd Ed. 2016. Available from: https:\/\/www.easp.es.","edition":"2"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1830782"},{"key":"e_1_3_3_29_1","unstructured":"Vargas M. Documento Marco sobre Enfermedad Renal Cr\u00f3nica dentro de la Estrategia de Abordaje a la Cronicidad en el SNS. Ministerio De Sanidad Servicios Sociales E Igualdad [Document on chronic kidney disease within the chronicity approach strategy in the NHS]. Ministerio de Sanidad Servicios Sociales e Igualdad [Internet]. 2015 [cited 2021 may 28]. Available from: https:\/\/www.sanidad.gob.es\/organizacion\/sns\/planCalidadSNS\/pdf\/Enfermedad_Renal_Cronica_2015.pdf."},{"key":"e_1_3_3_30_1","unstructured":"Ministerio de Sanidad. Conjunto M\u0131nimo Basico de Datos (CMBD) [Minimum basic data set (MBDS)]. Ministerio de Sanidad [Internet]. 2019 [cited 2021 July 1]. Available from: https:\/\/www.sanidad.gob.es\/estadEstudios\/estadisticas\/cmbdhome.htm."},{"key":"e_1_3_3_31_1","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos. Portal Farma. BotPLUS. Consejo General de Colegios Oficiales de Farmaceuticos [Internet]. 2021 [cited 2021 June 2]. Available from: https:\/\/botplusweb.portalfarma.com\/botplus.aspx."},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00752.x"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X65277"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00425.x"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462313000433"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/089686080202200107"},{"key":"e_1_3_3_37_1","unstructured":"National Institute for Health and Care Excellence. Clinical guideline [CG125]: chronic kidney disease (stage 5): peritoneal dialysis. National Institute for Health and Care Excellence. [Internet]. 2021 [cited 2021 July 21]. Available from: https:\/\/www.nice.org.uk\/guidance\/cg125."},{"key":"e_1_3_3_38_1","unstructured":"Ministerio de Sanidad. Listado de medicamentos afectados por las deducciones del Real Decreto-Ley 8\/2010 [List of drugs affected by the deductions of the Royal Decree-Law 8\/2010]. Ministerio de Sanidad. 2021 [cited 2021 July 1]. Available from: https:\/\/www.mscbs.gob.es\/profesionales\/farmacia\/pdf\/DeduccionesJulio2021.pdf."},{"key":"e_1_3_3_39_1","unstructured":"National Institute for Health and Care Excellence. Clinical guideline [NG107]: renal replacement therapy and conservative management. National Institute for Health and Care Excellence [Internet]. 2021 [cited 2021 July 21]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng107."},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7596-1"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.7446"},{"issue":"4","key":"e_1_3_3_42_1","first-page":"312","article-title":"Impact on clinical outcomes and health costs of deranged potassium levels in patients with chronic cardiovascular, metabolic, and renal conditions","volume":"74","author":"Jim\u00e9nez-Marrero S","year":"2021","unstructured":"Jim\u00e9nez-Marrero S, Cainzos-Achirica M, Monterde D, et\u00a0al. Impact on clinical outcomes and health costs of deranged potassium levels in patients with chronic cardiovascular, metabolic, and renal conditions. Rev Esp Cardiol. 2021;74(4):312\u2013320.","journal-title":"Rev Esp Cardiol"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479802"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00902-w"},{"key":"e_1_3_3_45_1","first-page":"S86","article-title":"The cost-effectiveness analysis of patiromer and renin-angiotensin-aldosterone system inhibitors therapy in diabetic nephropathy patients with hyperkalemia","volume":"24","author":"Bounthavong M","year":"2018","unstructured":"Bounthavong M, Adamson R, Dolan C, et\u00a0al. The cost-effectiveness analysis of patiromer and renin-angiotensin-aldosterone system inhibitors therapy in diabetic nephropathy patients with hyperkalemia. J Manag Care Spec Pharm. 2018;24:S86.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0709-3"},{"key":"e_1_3_3_47_1","volume-title":"An\u00e1lisis econ\u00f3mico del uso de patiromer en Espa\u00f1a [Economic analysis of the use of patiromer in Spain]","author":"De Sequera P","year":"2021","unstructured":"De Sequera P, Bover R, Ivanova Y, et\u00a0al. An\u00e1lisis econ\u00f3mico del uso de patiromer en Espa\u00f1a [Economic analysis of the use of patiromer in Spain]. M\u00e1laga (Spain): 22 Congreso Nacional de Hospitales y Gesti\u00f3n Sanitaria; 2021. Spanish."},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.01.008"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2022.2074193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:12:08Z","timestamp":1729163528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2022.2074193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/13696998.2022.2074193"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2022.2074193","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}